Transforming Pharmacy Care

PGx is the study of how a person's genes affect their response to medications. By using PGx, NavRx helps ensure patients get the right drug, at the right dose, the first time.

BioVerify™ is a medication verification and adherence solution that helps health plans, providers, and pharmacies confirm whether patients are actually taking prescribed medications, not just filling them.

MTM is a pharmacist-led service that reviews and optimizes medications for safety and effectiveness. Traditional MTM saves money and reduces hospitalizations and NavRx amplifies it with predictive intelligence and genomics.

ADEs are harmful effects from medications, including overdosing, underdosing, or drug interactions. ADEs account for thousands of hospitalizations each year. NavRx reduces ADEs by providing data-driven prescribing guidance.

STAR ratings are a CMS system for evaluating Medicare Advantage plans. Medication adherence and safety metrics directly impact STAR ratings, and higher scores mean higher reimbursement for plans.

GUIDE (Guiding an Improved Dementia Experience) is a CMS initiative to improve care for dementia patients by reducing avoidable hospitalizations and supporting caregivers.

Medication management that is guided by pharmacogenomics has been proven to reduce total cost of care, through fewer hospitalizations, reduced ADEs, and better adherence. At population scale, this translates into tens of millions in avoidable costs saved.

NavRx benefits the entire healthcare ecosystem, but patients are at the center. Patients receive safer prescriptions with fewer side effects, while health plans and health systems see cost savings, better outcomes, and improved performance. Providers gain predictive insights to strengthen patient trust, and pharma companies access rich datasets that drive drug discovery and commercialization.